A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

PHASE1TerminatedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

February 13, 2024

Study Completion Date

February 13, 2024

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Interventions
DRUG

H3B-8800 (RVT-2001)

H3B-8800 (RVT-2001) orally at specified doses and schedules.

Trial Locations (49)

22301

Virginia Cancer Specialist, Fairfax

28007

Hospital General Universitario Gregorio Marañon, Madrid

31008

Clinica Universidad de Navarra, Pamplona

32224

Mayo Clinic Jacksonville, Jacksonville

33136

University of Miami, Miami

48201

Karmanos Cancer Institute, Detroit

55905

Mayo Clinic, Rochester

77030

MD Anderson Cancer Center, Houston

78705

Texas Oncology, Austin

80012

Rocky Mountain Cancer Center, Aurora

85711

Arizona Oncology Associates, Tucson

91010

City of Hope, Duarte

94805

Institut Gustave Roussy, Villejuif

96218

City of Hope, Irvine

97401

Oncology Associates of Oregon, Eugene

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

02215

Dana Farber Cancer Institute, Boston

Unknown

Algemeen Ziekenhuis Klina, Brasschaat

AZ Sint-Jan Brugge Oostende AV, Bruges

Universiteit Gent, Ghent

University Hospitals Leuven, Leuven

CHU Amiens-Picardie, Amiens

Centre Hospitalier Universitaire d'Angers (CHU d'Angers), Angers

Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux

Centre Hospitalier - Le Mans, Le Mans

Hôpital Claude Huriez, Lille

Centre Hospitalier Lyon Sud, Pierre-Bénite

Azienda Ospedaliera Universitaria di Bologna - Policlinico S. Orsola Malpighi, Bologna

Fondazione IRCCS Cà Granda Ospedale Policlinico Maggiore, Milan

Fondazione IRCCS Policlinico San Matteo, Pavia

IRCCS Istituto Clinico Humanitas Cancer Center, Rozzano

National Cancer Center, Gyeonggi-do

Daegu Catholic University Medical Center, Daegu

Gachon University Gil Medical Center, Incheon

Asan Medical Center, Seoul

Hanyang University Seoul Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

Hospital Universitario Valle de Hebrón, Barcelona

Hospital Universitario Fundación Jiménez Díaz, Madrid

Complejo Asistencial Universitario de Salamanca, Salamanca

Hospital Universitario y Politécnico La Fe de Valencia, Valencia

Changhua Christian Hospital, Changhua

Chang-Gung Memorial Hospital, Chiayi, Chiayi City

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Hemavant Sciences GmbH

INDUSTRY

NCT02841540 - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter